Lifebit Biotech Ltd. announced the beginning of a long-term partnership with Boehringer Ingelheim to utilize Natural Language Processing (NLP) and Artificial Intelligence (AI) for the detection and early reporting of global disease outbreaks using real-world data harvested from scientific publications and other open sources.
Speculation regarding poorer outcomes for those with high cholesterol and/or heart disease infected with SARS-CoV-2 are well known. A real-world study published by the FH Foundation confirms Covid-19 increased heart attack rates significantly in patients with these conditions.
Researchers from the Francis Crick Institute and the Latvian Institute of Organic Synthesis developed a new compound that blocks a step in the life cycle of the mosquito-borne parasite that causes malaria.
A previously undisclosed intelligence report by the U.S. State Department shows that three scientists at China’s Wuhan Institute of Virology received hospital care in November 2019 for influenza-like symptoms. The findings were on a State Department fact sheet that said they went to the hospital “with symptoms consistent with both Covid-19 and common seasonal illness.”
BioSpace takes a look at a few of the highlights of the 24th annual meeting of the ASGCT, with researchers presenting cutting-edge work in the booming area of gene and cell therapy.
Boosted by increased clinical research business in 2020, Science 37 is planning a SPAC merger that will land itself on the Nasdaq and a company value of more than $1 billion and $280 million in gross proceeds.
According to separate studies, blood type does not affect susceptibility to Covid-19 in U.S. patients and an inhaled steroid commonly used to treat asthma can help keep patients with mild Covid-19 from getting sicker.
Florence Healthcare’s Senior Implementation Manager Amanda Korey presents a roadmap that not only fosters collaboration between sites, sponsors and CROs, but also results in robust user adoption across all stakeholder groups.
The first study to directly compare immune reactions between Pfizer’s and AstraZeneca’s Covid-19 vaccines found strong and broadly similar antibody responses in over-80-year-olds after a first dose of either shot, scientists said on April 14.
Topline results from a Phase II study show SAGE-324, Sage Therapeutics’ investigational oral neuroactive steroid GABAA receptor positive allosteric modulator, significantly reduced tremor score in adult patients with essential tremor.